Yahoo
NYSEArca - Delayed Quote USD

State Street Industrial Select Sector SPDR ETF (XLI)

180.91 +1.31 (+0.73%)
At close: June 18 at 4:00:00 PM EDT
181.19 +0.31 (+0.17%)
Pre-Market: 8:00:20 AM EDT
Trade XLI on Coinbase
Chart Range Bar
Loading chart for XLI
  • Previous Close 179.60
  • Open 182.50
  • Bid --
  • Ask --
  • Day's Range 180.45 - 182.90
  • 52 Week Range 141.28 - 182.92
  • Volume 8,057,410
  • Avg. Volume 9,407,119
  • Net Assets 30.22B
  • NAV 180.89
  • PE Ratio (TTM) 31.42
  • Yield 1.18%
  • YTD Daily Total Return 16.95%
  • Beta (5Y Monthly) 1.09
  • Expense Ratio (net) 0.08%

Under normal market conditions, the fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Industrial companies by the Global Industry Classification Standard, including securities of companies from the following industries: aerospace and defense; industrial conglomerates; marine transportation. It is non-diversified.

State Street Investment Management

Fund Family

Industrials

Fund Category

30.22B

Net Assets

1998-12-16

Inception Date

Performance Overview

View More

Trailing returns as of 6/19/2026. Category is Industrials.

YTD Return

XLI
16.95%
Category
13.30%

1-Year Return

XLI
28.91%
Category
45.64%

3-Year Return

XLI
21.50%
Category
21.72%

People Also Watch

Holdings

View More

Top 10 Holdings (40.29% of Total Assets)

Symbol Company % Assets
CAT 7.55%
GE 6.29%
GEV 4.84%
RTX 4.47%
BA 3.36%
UNP 2.89%
ETN 2.88%
HON 2.80%
UBER 2.68%
DE 2.53%

Sector Weightings

Research Reports

View More
  • Biogen Earnings: Strong First Quarter, Eventful Year Ahead

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • Biogen Earnings: Eventful Year Ahead Despite Expected Decline in Revenue

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • AI driving growth, raising target price to $450

    Taiwan Semiconductor Manufacturing Company Ltd., headquartered in Hsinchu, Taiwan, was founded in 1987 and pioneered the pure-play foundry or 'merchant fab' model. The company serves both integrated semiconductor producers who outsource a portion of their production as well as 'fabless' semiconductor producers who outsource all manufacturing. Taiwan Semi serves over 500 semiconductor customers, producing more than 11,500 distinct products while providing a broad range of advanced, specialty, and advanced packaging technologies.

    Rating
    Price Target
  • ASML Earnings: Outlook Is Magnificent, but Valuation Overshoots Our Fair Value Estimate

    ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: